Literature DB >> 27296827

Lung clearance index for monitoring early lung disease in alpha-1-antitrypsin deficiency.

Susanne I Fuchs1, Nicolaus Schwerk2, Klaus Pittschieler3, Frank Ahrens4, Winfried Baden5, Robert Bals6, Sebastian Fähndrich6, Wolfgang Gleiber7, Matthias Griese8, Georg Hülskamp9, Thomas Köhnlein10, Ludmilla Reckling7, Ernst Rietschel11, Doris Staab12, Monika Gappa13.   

Abstract

Patients with alpha-1-antitrypsin deficiency (AATD) and a PI-ZZ genotype are at high risk to develop severe emphysema during adulthood. However, little is known about early stages of emphysema and disease manifestation in other PI-types. Spirometry is commonly used for monitoring although early manifestation of emphysema is suspected within the peripheral airways that are not accessible by forced expiratory manoeuvres. We hypothesized that the Lung Clearance Index (LCI) derived from multiple breath nitrogen-washout (N2-washout) is useful to bridge this diagnostic gap. Patients from age 4 years onward and different PI-types performed N2-washout and spirometry. Results were compared to controls. 193 patients (4-79 years, 75% PI-ZZ) and 33 controls (8-60 years) were included. Mean (SD) LCI in patients was 9.1 (3.1) and 6.3 (0.6) in controls (p ≤ 0.001). 47% of adult patients with other than PI-ZZ genotypes and 39% of all patients with normal spirometry had abnormal LCIs. The LCI measured by N2-washout discriminates between patients with AATD and controls, reflects AATD related lung disease in all stages and appears to identify early peripheral lung changes in younger age than spirometry. We conclude that a normal spirometry does not exclude presence of AATD related lung disease even in genotypes other than PI-ZZ.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27296827     DOI: 10.1016/j.rmed.2016.04.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  Lung Clearance Index (LCI) in Patients with Bronchiolitis Obliterans: A Preliminary Report and Comparison to Cystic Fibrosis Patients.

Authors:  Michal Gur; Karin Yaacoby-Bianu; Anat Ilivitzki; Ronen Bar-Yoseph; Vered Nir; Fahed Hakim; Yazeed Toukan; Lea Bentur
Journal:  Lung       Date:  2016-08-31       Impact factor: 2.584

Review 2.  Small airways disease: time for a revisit?

Authors:  James A Stockley; Brendan G Cooper; Robert A Stockley; Elizabeth Sapey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-08-07

Review 3.  Catching "Early" COPD - The Diagnostic Conundrum.

Authors:  Kay Por Yip; Robert A Stockley; Elizabeth Sapey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-04-13

4.  Functional lung MRI for regional monitoring of patients with cystic fibrosis.

Authors:  Till F Kaireit; Sajoscha A Sorrentino; Julius Renne; Christian Schoenfeld; Andreas Voskrebenzev; Marcel Gutberlet; Angela Schulz; Peter M Jakob; Gesine Hansen; Frank Wacker; Tobias Welte; Burkhard Tümmler; Jens Vogel-Claussen
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

Review 5.  An overview of exacerbations of chronic obstructive pulmonary disease: Can tests of small airways' function guide diagnosis and management?

Authors:  Nowaf Y Alobaidi; James A Stockley; Robert A Stockley; Elizabeth Sapey
Journal:  Ann Thorac Med       Date:  2020-04-03       Impact factor: 2.219

6.  Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease.

Authors:  Nan He; Xiaoming Liu; Amber R Vegter; T Idil A Evans; Jaimie S Gray; Junfeng Guo; Shashanna R Moll; Lydia J Guo; Meihui Luo; Ningxia Ma; Xingshen Sun; Bo Liang; Ziying Yan; Zehua Feng; Lisi Qi; Arnav S Joshi; Weam Shahin; Yaling Yi; Katherine N Gibson-Corley; Eric A Hoffman; Kai Wang; Christian Mueller; John F Engelhardt; Bradley H Rosen
Journal:  JCI Insight       Date:  2022-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.